- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: Gene mapping.
Displaying page 1 of 1.
EudraCT Number: 2017-005197-19 | Sponsor Protocol Number: SIPPET2 | Start Date*: 2018-08-01 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||
Full Title: Inhibitor development in previously untreated patients with severe haemophilia A, first treated with plasma-derived factor VIII and then switched to recombinant product: an international, multicent... | |||||||||||||
Medical condition: Severe hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011186-88 | Sponsor Protocol Number: ABB-09-001 | Start Date*: 2009-09-08 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI | |||||||||||||
Full Title: Desarrollo de inhibidores en pacientes no tratados previamente (PUP) o en pacientes mínimamente tratados con componentes sanguíneos (MBCTP) al ser expuestos a concentrados de derivados plasmáticos ... | |||||||||||||
Medical condition: El estudio es un ensayo clínico abierto, aleatorizado, controlado, prospectivo, multicéntrico, internacional e independiente sobre la frecuencia de formación de inhibidores en pacientes no tratados... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Completed) PT (Completed) FR (Ongoing) DE (Completed) AT (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005683-41 | Sponsor Protocol Number: RIOTB2015 | Start Date*: 2016-03-16 | |||||||||||||||||||||
Sponsor Name:Sven O. Skouby, Professor, MD, DMSc. Unit of reproductive Medicine, Herlev/Gentofte Hospital | |||||||||||||||||||||||
Full Title: REDUCING THE IMPACT OF OVARIAN STIMULATION - THE RIOT PROJECT RIOT STUDY B: MAPPING THE ENDOCRINE DETERMINANTS OF OVARIAN STIMULATION TO OPTIMIZE OUTCOMES IN FRESH EMBRYO TRANSFER CYCLES ... | |||||||||||||||||||||||
Medical condition: Infertility | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004246-20 | Sponsor Protocol Number: 20810 | Start Date*: 2018-03-06 | ||||||||||||||||
Sponsor Name:Bayer Consumer Care AG | ||||||||||||||||||
Full Title: A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers Formerly: A Phase 1/2 Study of the TRK Inhibitor LOXO-1... | ||||||||||||||||||
Medical condition: NTRK fusion cancers previously treated with a TRK inhibitor | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) FR (Completed) DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IE (Completed) IT (Prematurely Ended) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-002554-23 | Sponsor Protocol Number: GENA-05 | Start Date*: 2013-02-19 | |||||||||||
Sponsor Name:OCTAPHARMA AG | |||||||||||||
Full Title: Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII in Previously Untreated Patients with Severe Haemophilia A | |||||||||||||
Medical condition: Severe Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) PL (Completed) DE (Completed) ES (Completed) FR (Completed) PT (Completed) SI (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004405-64 | Sponsor Protocol Number: MT-2-03 | Start Date*: 2019-03-07 | |||||||||||
Sponsor Name:Minoryx Therapeutics BE, SA | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients with Friedreich’s Ataxia | |||||||||||||
Medical condition: Friedreich’s Ataxia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000828-19 | Sponsor Protocol Number: NN9535-4662 | Start Date*: 2021-01-25 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Renal mode of action of semaglutide in patients with type 2 diabetes and chronic kidney disease | ||||||||||||||||||
Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) FR (Completed) IT (Completed) ES (Ongoing) DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003427-38 | Sponsor Protocol Number: MOTIVATE | Start Date*: 2020-03-12 | |||||||||||
Sponsor Name:HZRM – Hämophilie-Zentrum Rhein Main GmbH | |||||||||||||
Full Title: MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial | |||||||||||||
Medical condition: Inhibitor-Positive patients with Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000667-24 | Sponsor Protocol Number: ST-920-201 | Start Date*: 2019-11-12 | |||||||||||
Sponsor Name:Sangamo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase I/II, Multicenter, Open-Label, SingleDose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Dise... | |||||||||||||
Medical condition: Fabry Disease (X-linked lysosomal storage disease) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
